The possibilities for personalised vaccines in all types of cancer are revealed today in a lecture from Dr Harpreet Singh at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.
“One of the biggest hurdles in cancer immunotherapy is the discovery of appropriate cancer targets that can be recognised by T-cells,” said Singh, who is scientific coordinator of the EU-funded GAPVAC phase I trial which is testing personalised vaccines in glioblastoma, the most common and aggressive brain cancer. “In the GAPVAC trial we will treat glioblastoma patients with vaccines that are ideal for each patient because they contain personalised antigens.”1
For all patients in the GAPVAC study, researchers will identify genes expressed in the tumour, peptides presented on the human leukocyte antigen (HLA) receptor (i.e. peptides which will be seen by T-cells), cancer specific mutations, and the ability of the immune system to mount a response to certain antigens. Based on this information, two vaccines, called actively personalised vaccines (APVACs), will be constructed and administered following conventional surgery.
The first vaccine will be prepared from a warehouse of 72 targets previously identified by the researchers as relevant for treatment in glioblastoma. These peptides have been manufactured and put on the shelf ready to be vaccinated in patients. Patients will be given a cocktail of the peptides they express and which their immune system can mount a response to.
Singh said: “A patient may express 20 of these 72 targets on their tumour, for example. If we find that the patient’s immune system can mount responses to 5 of the 20 targets, we mix the 5 peptides and give them to the patient. We mix the peptides off the shelf but the cocktail is changed for each patient because it is matched to their biomarkers.”
The second vaccine is synthesised de novo based on a mutated peptide expressed in the tumour of the patient. Singh said: “That peptide is not in our warehouse because it just occurs in this one single patient. The patient receives APVAC-1 and APVAC-2 in a highly personalised fashion in a way that I think has never been done for any patient.”
He added: “GAPVAC has two major goals. One is to show that personalised vaccines are feasible, since this is one of the most complicated trials ever done in cancer immunotherapy. The second is to show that we can mount far better biological responses in these patients compared to vaccination with non-personalised antigens.”
Singh’s previous research has shown that vaccination with non-personalised antigens leads to better disease control and longer overall survival in phase I and phase II clinical studies in patients with renal cell cancer.2
Singh said: “For the non-personalised vaccines we used off-the-shelf peptide targets that were shared by many patients with a particular cancer. Using this approach we have successfully vaccinated patients with renal cell cancer, colorectal cancer and glioblastoma.”
He added: “During this research we identified other targets that appeared in very few patients or even, in extreme cases, in a single patient. Often these rarer peptides are of better quality, meaning they are more specifically seen in cancer cells and occur at higher levels. This led us to start developing personalised cancer vaccines which contain the ideal set of targets for one particular patient. We hope they will be even more effective than the off-the-shelf vaccines.”
The Latest on: Personalised Vaccines
via Google News
The Latest on: Personalised Vaccines
- OHA launches effort to ease vaccine scheduling for seniorson March 8, 2021 at 10:07 am
The Oregon Health Authority and All4Oregon launched a new system this weekend aimed to simplify the process of signing up to receive the COVID-19 vaccine.
- All K-12 School Employees Now Eligible for COVID-19 Vaccine But Supplies Remain a Concernon March 7, 2021 at 3:16 pm
The San Diego County Office of Education has set up a separate vaccine appointment system for school employees in hopes of streamlining the process, but supply issues could affect how quickly the ...
- Mass. residents find other paths to secure COVID-19 vaccine appointmentson March 5, 2021 at 10:28 pm
Hospitals and health care systems, back with fresh shipments of the vaccine, are leading a push for people to get appointments in alternative ways through hot lines, phone calls, e-mails, and texts to ...
- Vaccine appointments canceled after the wrong people got into the systemon March 5, 2021 at 9:28 pm
COVID-Check Colorado is a philanthropic group helping with the COVID vaccine rollout. They canceled 1,100 appointments after people who are too young were scheduled.
- 57% of Those Who Won't Get COVID Vaccine Say They Generally Avoid Them: Pollon March 5, 2021 at 4:32 pm
People opposed to getting the vaccine may not identify as anti-vaxxers. In fact, they may have fears or beliefs that can be changed through emotional messaging.
- Europe debates vaccine passports as a way to save summer tourismon March 5, 2021 at 2:08 pm
Ahead of Europe's summer holiday season, some top destinations such as Greece and Spain are pushing the European Union to introduce digital "vaccine passports" to ease entry for visitors — and their ...
- CDC: Allergy to COVID vaccine very rareon March 5, 2021 at 1:50 pm
While many are willing to go to great lengths to get the COVID-19 vaccine, other people are questioning whether it poses health risks.But health officials maintain that the three vaccines approved for ...
- Inovio spinout Geneos closes $12M financing round to advance personalized cancer therapyon March 4, 2021 at 7:47 am
Geneos Therapeutics, an immunotherapy company spun out of Inovio Pharmaceuticals in 2019, has closed $12 million in an equity financing. The expansion of the Plymouth Meeting company's Series A round ...
- Find out what vaccine group you're inon March 4, 2021 at 4:47 am
Gov. Roy Cooper announced the state will begin Phase 3 vaccines Feb. 24, giving priority to teachers. Here's when everyone else might be able to get their shot.
- The COVID Vaccine Side Effects To Knowon March 3, 2021 at 8:30 pm
Here’s what you need to know about possible side effects of the COVID-19 vaccines. Because the Pfizer-BioNTech and Moderna shots are both messenger RNA vaccines, a.k.a. mRNA vaccines. They require two ...
via Bing News